For many humanities graduate students, the pandemic meant pauses to in-person research, delayed plans for graduation and disrupted career prospects.
On May 1, 2020, Northwestern University Graduate Workers hosted an International Workers’ Day sit-in to advocate for #universal1yr, an additional year of funding for all graduate workers at Northwestern.
Now, about a year after the NUGW action, graduate workers are experiencing varying degrees of delays to research, NUGW co-chair and Ph.D. candidate Charlotte Rosen said.
“Everyone’s experience is probably a little bit different, and some people have slowed down more than others,” Rosen said. “I think it’s pretty safe to say that the majority of graduate workers have experienced some kind of a slowdown.”
Study of Soberana Plus vaccine candidate continues
Study of Soberana Plus vaccine candidate continues
20 de abril de 2021, 0:0Havana, Apr 20 (Prensa Latina) Studies of Cuba s Soberana Plus vaccine candidate continue in this capital in order to reinforce the protection and responsiveness of Covid-19 convalescing patients in the face of a possible reinfection. This is phase II A of clinical trials of this vaccine candidate from the Finlay Vaccines Institute (IFV), whose study is being carried out at the Hematology and Immunology Institute, in this capital.
The vaccination of a score of people of the 450 convalescing patients included in this phase of the study started on Saturday.
Cuba prepares to protect Covid-19 convalescents
Cuba prepares to protect Covid-19 convalescents
Havana, Jan 25 (Prensa Latina) Cuba is currently advancing in the development of a clinical trial in patients convalescing from Covid-19, who had a mild clinical record or were asymptomatic. The clinical development program of Soberana 01 (vaccine candidate against Covid-19) includes the assessment in convalescents, a population that has not been in the target of vaccines, highlighted on Twitter the director of Research of the Finlay Institute of Vaccines, Dagmar Garcia.
Covid-19 cases who had been reinfected by the novel coronavirus have been reported worldwide, even with much more acute and severe forms of the disease; therefore, the country also seeks to protect this risk group.
Cuba seeks to protect population against Covid-19
Cuba seeks to protect population against Covid-19
Havana, Jan 25 (Prensa Latina) Cuban scientists and health personnel are currently making progress in clinical trials of anti-Covid-19 vaccine candidates developed in this country with the aim of protecting the entire population.
Vaccine candidate Soberana 01 is going through clinical Phase I trial in convalescent patients who had mild symptoms, those who were asymptomatic or had positive test results.
The trial began on January 9 with the participation of 30 volunteers aged 19 to 59, who were in contact with the virus and currently have a negative PCR test.
These patients received a single dose of the vaccine on January 16 and from that moment, they maintain a strict monitoring in consultations and with the scientists.